Epitalon and the 503A Bulks List: FDA's Review and the July 2026 PCAC Vote

Update (October 2026): At the July 24, 2026 meeting, the Pharmacy Compounding Advisory Committee voted 7–4 (1 abstention) to recommend adding Epitalon (free base and acetate) to the 503A Bulks List, going against the FDA staff proposal. The vote is advisory: Epitalon is not on the 503A Bulks List until FDA completes notice-and-comment rulemaking, which is expected to run into 2027, and FDA can still decline to list it. For current status, see our FDA Peptide Status Tracker.

The Short Answer

At the July 24, 2026 PCAC meeting, FDA proposed that Epitalon (free base) and Epitalon acetate not be added to the 503A Bulks List. The nomination (later withdrawn, with FDA proceeding) was evaluated for insomnia by the subcutaneous route. FDA found the effectiveness and safety evidence insufficient.

What Epitalon Is

Epitalon is a four-amino-acid peptide (Ala-Glu-Asp-Gly) developed within the Russian school of bioregulator research and associated with the pineal gland and melatonin regulation. It is widely marketed as a longevity and anti-aging peptide. For a fuller picture, see our Epitalon longevity overview.

Characterization: "Not Well-Characterized"

FDA deemed the substance not well-characterized, citing inconsistent naming conventions (INN, USAN, IUPAC) and missing data relevant to critical quality attributes needed to establish identity, purity, and strength. The acetate is reported stable below −20°C.

Historical Use: Unclear

FDA found the extent of epitalon compounding unclear. Public information suggests use in compounding since at least 2018, but no pharmacies were found compounding epitalon, and it was unclear whether products sold online are compounded. The agency judged the record too limited to understand historical compounding use.

Effectiveness: Melatonin Changes, but No Insomnia Outcomes

FDA concluded there is a lack of evidence to support effectiveness for insomnia. Available clinical information discusses epitalon's effects on melatonin or its metabolites, but FDA identified no studies evaluating use in patients with insomnia — particularly by the proposed subcutaneous route. The agency noted that a change in melatonin levels, without corresponding clinical-outcome data, doesn't establish therapeutic effect, and that multiple FDA-approved insomnia therapies exist.

Safety: No Human Data for the Proposed Route

Pharmacologically, epitalon's reported ability to raise serum melatonin suggests it could influence sleep-wakefulness, but FDA found no nonclinical studies assessing behavioral or EEG sleep endpoints, and the mechanism by which epitalon regulates melatonin in vivo remains unknown. On genotoxicity, intermittent dosing in female mice did not increase chromosome aberrations in bone-marrow cells. Critically, FDA concluded there are no clinical data to support the safety of epitalon in humans, particularly by the proposed SC route, which raises immunogenicity concern from aggregation and impurities.

What It Means for Physicians

Epitalon was not FDA-approved and remains so. See the pillar overview and confirm access with your 503A compounding partner.

Key Takeaways

• FDA is proposing that Epitalon (free base and acetate) not join the 503A Bulks List.
• Epitalon can alter melatonin levels, but no insomnia clinical-outcome studies were identified — especially for the SC route.
• No human safety data support subcutaneous use; immunogenicity is a concern.
• FDA-approved insomnia therapies already exist, weighing against listing.

Frequently Asked Questions

Is epitalon banned by the FDA?
No. FDA is proposing that epitalon not be added to the 503A Bulks List — an advisory-committee proposal, not a final rule. Epitalon was never FDA-approved.

What is epitalon?
A four-amino-acid peptide (Ala-Glu-Asp-Gly) associated with the pineal gland and melatonin regulation, marketed as a longevity/anti-aging peptide.

Does epitalon help with sleep?
FDA found data on epitalon's effect on melatonin levels but no studies evaluating clinical outcomes in insomnia patients, so effectiveness for insomnia is not established.

Was epitalon found to be genotoxic?
In the studies FDA reviewed, intermittent epitalon dosing in female mice did not increase chromosome aberrations in bone-marrow cells — but this does not substitute for the missing human safety data.

Track Live FDA Peptide Status

Regulatory status changes as PCAC hearings and FDA determinations roll out. Bookmark our FDA Peptide Status Tracker 2026 for the latest category and PCAC updates on every peptide.